PIQUR Therapeutics AG

Gegründet: August 2011

The creation of a pharmaceutical spin-off company that develops and commercializes personalized cancer medicines

PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the University of Basel, focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. Both PI3K and mTOR are clinically validated drug targets in oncology.

PIQUR’s lead compound, PQR309, is a novel, balanced pan-class 1 PI3K/mTOR inhibitor formulated for oral administration. Preclinical studies demonstrated that PQR309 is a highly selective kinase inhibitor, penetrating blood-brain barrier with potent in vitro as well as in vivo antitumor activity. A first-in-man clinical Phase 1 study was successfully completed and the maximum tolerated dose has been determined and has shown promising activity. PQR309 is currently engaged in multiple Phase 1 and Phase 2 studies as a single agent and as combination therapy.

Milestones / News

Milestone 17.02.2016

Eisai and PIQUR sign landmark collaboration agreement to investigate Halaven® (eribulin) and PQR309 in hard to treat form of breast cancer

Funding Activity 16.07.2015

PIQUR raises CHF 18 Million in Series A2 financing

Milestone 05.06.2015

PIQUR named the best start-up in Switzerland

Milestone 27.05.2015

PIQUR announces positive Phase 1 study results and the start of Phase 2 of PQR309

Milestone 10.11.2014

PIQUR wins the Northwest Switzerland Young Entrepreneurs’ Award 2014

Funding Activity 08.04.2014

Versant Ventures invests CHF 11 million in PIQUR and brings further industry expertise to the Board

Funding Activity 21.01.2014

PIQUR launches Phase I study with its lead compound PQR309 and successfully completes Series A financing round

Funding Activity 05.09.2013

PIQUR closed third seed financing round and received Eurostars grant

Milestone 22.08.2013

Positive results of regulatory toxicology studies pave the way for first in human clinical trials

Funding Activity 11.02.2013

PIQUR secured funding to start the development of innovative anti-cancer therapies